Artist Visas
Debate between Seema Kennedy and Kerry McCarthy(4 years, 7 months ago)
Westminster HallRead Full debate Read Hansard Text Read Debate Ministerial Extracts
Westminster Hall is an alternative Chamber for MPs to hold debates, named after the adjoining Westminster Hall.
Each debate is chaired by an MP from the Panel of Chairs, rather than the Speaker or Deputy Speaker. A Government Minister will give the final speech, and no votes may be called on the debate topic.
This information is provided by Parallel Parliament and does not comprise part of the offical record
Kerry McCarthy (Bristol East) (Lab)
I apologise for not having been able to be present at the start of the debate.
On the point about fees, I have many cases where people’s visa applications are rejected for minor points, because a document has gone missing or they did not provide something with the right date. If it is rejected, they have no right of appeal, so they have to start all over again, not quite knowing what they did wrong. Would it not be easier if officials could just phone people up and say, “You haven’t sent in a copy of your landlord’s agreement”, or whatever is required? It would save so much money.
Seema Kennedy
Due to the nature and the great volume of visa applications, there are obviously cases where documents go missing at either end or where there is not clarity. If the hon. Lady has specific examples—
Seema Kennedy
My pile of letters is like the magic porridge pot—it never gets to the bottom. I am very happy to look at them.
I am aware of some of the problems experienced by international artists coming to the UK, to which we have heard reference today. There have been some refusals. I realise that delays or errors can have serious personal consequences for the individual, and reputational and economic consequences for the UK organisers of events. As I have said on several occasions, however, I am committed to making the visitor system as simple and straightforward as possible, and to ensuring that decisions are right first time. That is important. We want to continue to deliver an excellent service for our customers.
The hon. Member for Edinburgh North and Leith referred to passports being lost. Everybody has the option to use the “Keep My Passport When Applying” service, but if she writes to me with a specific example of a lost passport, I will happily look into it.
The hon. Member for Glasgow North is a great champion of issues relating to Africa in this place. My predecessor met the hon. Member for Newcastle upon Tyne Central (Chi Onwurah), who is the chair of the all-party parliamentary group for Africa. We are keen to look at that issue. Visa applications from African nationals are at their highest level since 2013. The percentage of African nationals whose applications were granted is up by 4% on 10 years ago. The average issue rate for non-settlement visa applications submitted in the Africa region is consistent with the average issue rate for the last three years, which is 75%. There are problems in some cases, however; the hon. Gentleman referred to the difficulties that some of the people with whom he is engaged in Malawi have encountered with the new hub-and-spoke configuration of the system. I will keep that under review.
The hon. Member for Glasgow East (David Linden) talked about an immigration system with regional variations. We are clear that our future immigration system must work for every nation, region and community in the UK. We remain invested in fully engaging with the devolved Administrations. A regional immigration system is clearly problematic because we do not have internal controls. The Department considers that, given the complexity and scale of the effort, distortions or unintended consequences could result from divergent approaches in the nations of the UK. The Migration Advisory Committee has noted that it does
“not consider that there is a strong economic case for regional differentiation in migration policy”.
On the hon. Gentleman’s point about people who have absconded, I am afraid that we cannot reveal numbers. If an individual claims asylum, we cannot reveal it, because it could have an impact on his or her case. It is also difficult to quantify the number of people who are here illegally and have not brought themselves to the attention of Immigration Enforcement.
I turn to the future. The Prime Minister has been clear that we are leaving the European Union on 31 October, which will mean that freedom of movement as it stands will end when the UK leaves the EU. EU citizens will still be able to come to the UK on holiday and for short trips, but the arrangements for people coming to the UK for longer periods of time and for work and study will change. Details of other changes immediately after 31 October, and improvements for the new immigration system, are being developed.
I finish by paying tribute to all hon. Members who have spoken today. They take the issue of our cultural life, the free exchange of ideas and the contribution of artists to our economy very seriously, as do the Government. In the Home Office, on visas, we have to balance that against keeping our borders safe and secure. I look forward to engaging with hon. Members on this issue in the future.
Cystic Fibrosis Drugs: Orkambi
Debate between Seema Kennedy and Kerry McCarthy(4 years, 10 months ago)
Westminster HallRead Full debate Read Hansard Text Read Debate Ministerial Extracts
Westminster Hall is an alternative Chamber for MPs to hold debates, named after the adjoining Westminster Hall.
Each debate is chaired by an MP from the Panel of Chairs, rather than the Speaker or Deputy Speaker. A Government Minister will give the final speech, and no votes may be called on the debate topic.
This information is provided by Parallel Parliament and does not comprise part of the offical record
Seema Kennedy
As always, the shadow Minister makes an excellent point. Crown use licensing is not something that any Government would consider lightly. It is very rarely used in health. It has probably not been used—my officials will correct me if I am wrong—since the 1970s.
The ideal thing is to get a deal, and deals have been done with other pharmaceutical companies; that is the point I want to make. As I have said, Vertex is an outlier in this regard, but that does not mean that I do not have an obligation to look at other options. I will do that.
Kerry McCarthy
I really welcome the fact that the Minister is saying so passionately that she feels she has a moral obligation to act. The question is: when? I say that because Vertex has been in these talks for a very long time now. How much longer will it be given before the Minister decides to look at the other options?
Seema Kennedy
Now. We will look at other options to consider what other methods we can use. As the hon. Member for Washington and Sunderland West said, Crown use licensing has other risks, so the best option is to get a deal. However, we will look at other methods that might enable families to receive the drugs they need.
Some Members have said that Orkambi is available in other countries and asked, “So why not here?” Although that is true, it is also true that other countries have faced problems in agreeing an acceptable price with Vertex; around 50% of the global cystic fibrosis population is unable to access Orkambi. It is not approved for reimbursement in Spain, which I have touched on, or in Portugal, and it is not used routinely in France. It is also of note that the Canadian equivalent of NICE has rejected the drug, saying that the benefit of Orkambi is small and uncertain.
We do not have sight of specific commercial agreements where Orkambi is approved and we do not have the same population needs, as we know, because of the specific population that the UK has; compared with other countries, the UK has a very high proportion of people with cystic fibrosis. So I am not able to make comparisons with other countries. Cystic fibrosis affects about 10,500 people in the United Kingdom—a far higher figure than in other countries. It represents 12% of the global cystic fibrosis population. The UK is a very important market for Vertex.
I thank all Members who have spoken so passionately here today. In particular, I thank the people who have joined us here in the Gallery; I pay tribute to them for all that they do to support their family members. I also thank those people, such as Lucy Baxter, who work so hard to raise awareness of this issue. I thank members of the Health and Social Care Committee, which is carrying out a very thorough and transparent inquiry into this issue, helping to shine a light on it.
As we have heard in great and moving detail today, cystic fibrosis is a devastating, life-limiting condition, and the bravery of those affected should be an inspiration to us all. Drugs that improve sufferers’ quality of life should be available where appropriate, and I urge Vertex to do everything it can to price its medicines fairly and in a way that reflects the health benefits to patients.
NHS England and NICE will, of course, continue their efforts to reach an agreement with Vertex. Access to treatment for all patients is, and always will be, a priority for this Government. My Department has a moral obligation to look at other options now, and that is what we shall do.